GGrantIndex
← Leaderboards

Charlotte Jane Sumner

Johns Hopkins University

$12,001,647
Attributed
$12,001,647
Total exposure
7
Grants
7
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $1.3M · FY200625
$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$12,001,647 · 7

By mechanism

R01$5,669,135 · 4
R35$5,290,574 · 1
K22$570,360 · 1
R21$471,578 · 1

Top collaborators

No co-investigators on record.

Most similar at Johns Hopkins University

Same institution · by research overlap

Others in their field

Top investigators on “Mutation

Research focus

MutationGenesSpinal Muscular AtrophyMuscle WeaknessMotorMotor NeuronsMotor Neuron DiseaseInheritedPhenotypeTherapeutic TargetInsightPathologyCellsProteinsInduced Pluripotent Stem CellImpairmentMortalityGeneticHistone Deacetylase InhibitorMolecularNovel Therapeutic InterventionBasePharmaceutical PreparationsNeonatal

Grant awards (26)

Translating Pathomechanisms into Treatment for Spinal Muscular Atrophies$1,047,692
R35 · FY2025 · NS · contact PI
Translating Pathomechanisms into Treatment for Spinal Muscular Atrophies$1,016,262
R35 · FY2024 · NS · contact PI
Translating Pathomechanisms into Treatment for Spinal Muscular Atrophies$1,002,012
R35 · FY2023 · NS · contact PI
Translating Pathomechanisms into Treatment for Spinal Muscular Atrophies$1,002,012
R35 · FY2022 · NS · contact PI
Translating Pathomechanisms into Treatment for Spinal Muscular Atrophies$163,750
R35 · FY2022 · NS · contact PI
Translating Pathomechanisms into Treatment for Spinal Muscular Atrophies$1,058,846
R35 · FY2021 · NS · contact PI
TRPV4 links the blood-neural barrier to motor neuron dysfunction$496,963
R01 · FY2020 · NS · contact PI
Targeting a SMN lncRNA for the treatment of SMA$426,710
R01 · FY2020 · NS · contact PI
Impaired axon development in SMA$417,505
R01 · FY2020 · NS · contact PI
Targeting a SMN lncRNA for the treatment of SMA$426,710
R01 · FY2019 · NS · contact PI
Impaired axon development in SMA$417,505
R01 · FY2019 · NS · contact PI
Impaired axon development in SMA$417,346
R01 · FY2018 · NS · contact PI
Targeting a SMN lncRNA for the treatment of SMA$322,986
R01 · FY2018 · NS · contact PI
Targeting a SMN lncRNA for the treatment of SMA$496,813
R01 · FY2017 · NS · contact PI
Targeting a SMN lncRNA for the treatment of SMA$456,588
R01 · FY2016 · NS · contact PI
Targeting a SMN lncRNA for the treatment of SMA$46,708
R01 · FY2016 · NS · contact PI
A model of TRPV4 channelopathy$207,789
R21 · FY2015 · NS · contact PI
A model of TRPV4 channelopathy$263,789
R21 · FY2014 · NS · contact PI
Muscle and neuromuscular junctions in spinal muscular atrophy$333,192
R01 · FY2013 · NS · contact PI
Muscle and neuromuscular junctions in spinal muscular atrophy$345,526
R01 · FY2012 · NS · contact PI
Muscle and neuromuscular junctions in spinal muscular atrophy$345,768
R01 · FY2011 · NS · contact PI
Muscle and neuromuscular junctions in spinal muscular atrophy$349,529
R01 · FY2010 · NS · contact PI
Muscle and neuromuscular junctions in spinal muscular atrophy$369,286
R01 · FY2009 · NS · contact PI
Regulation of the survival motor neuron gene$190,900
K22 · FY2008 · NS · contact PI
Regulation of the survival motor neuron gene$190,900
K22 · FY2007 · NS · contact PI
Regulation of the survival motor neuron gene$188,560
K22 · FY2006 · NS · contact PI